



How cell cycle transcription factors inhibit neural proliferation

Mauger A.

Submitted: August 6, 2023, Revised: version 1, January 4, 2023, version 2, March 13, 2024

Accepted: March 13, 2024

Abstract

Student Adult neurons are incapable of cellular proliferation due to their abnormal cell cycle. Upon maturation, post-mitotic neurons face terminal cell cycle arrest at the G1/S checkpoint. If cell cycle re-entry is attempted, neurons trigger pro-apoptotic pathways that kill the cell before any proliferative progress can be made. These processes inhibiting neural replication are highly influenced by cell cycle transcription factors, which face neuro-specific regulations to induce such unique cellular events. This paper examines how the regulations and differential functions of neural cell cycle transcription factors facilitate neurons' inability to proliferate. Specifically, we review how BHLH, E2F, SMAD, FOXO1, SP1, c-MYC, p53, and Brn-3a regulate cell cycle arrest, and how E2F1, FOXO1, C-JUN, and p53 facilitate neural apoptosis upon attempted cell cycle re-entry.

Keywords

Neuron, Cell cycle arrest, Transcription factor, Apoptosis, G0 Phase, Anti-proliferation, CDK inhibition, Neurodegenerative disease, BRDU, Partial cell cycle entry

Auburne Mauger, STEM School Highlands Ranch, 8773 S Ridgeline Blvd, Highlands Ranch, CO 80129 USA, auburne.mauger@gmail.com

1 Introduction

In the vertebrate central nervous system (CNS), neurons are a unique cell type that lack proliferative action due to their abnormal cell cycle.

The general cell cycle consists of 4 main phases: G1, S, G2, and M. In G1, the first phase after a new cell is formed, cells grow, replicate organelles, and acquire nutrients. Upon replicative stimuli, cells transition from G1 to S. This process is highly regulated by a G1/S checkpoint that ensures cells possess all S phase prerequisites. After passing this checkpoint, cells move into the S phase where DNA is completely replicated. They then transition into G2, a final growth phase, where they prepare for division. Finally, cells prepared to replicate pass through a final G2/M checkpoint into the M phase where they undergo mitosis (division into two identical daughter cells). This process then repeats in proliferating cells, contributing to organismal longevity by allowing tissues to grow and regenerate upon inevitable damage (1).

Transitions between cell cycle phases are highly regulated by cyclins, proteins that rise and fall throughout the cell cycle to signal activation of key events. As cyclic levels rise, they bind to and activate cyclin-dependent kinases (CDKs), which phosphorylate proteins that activate cell cycle progression genes. Transduction of these genes is also highly dependent on the activity of cell cycle transcription factors (TFs). TFs are proteins that control DNA transcription rate and are essential for the progression of the cell cycle at proper times and locations in proliferating cells (2).

In neurons, the activity of cell cycle TFs has the exact opposite effect. While post-mitotic neurons undergo terminal differentiation, cell cycle TFs inhibit rather than activate the G1/S checkpoint. This action arrests the neural cell cycle in a terminal state of G1 termed G0. Neural TF's also prevent cell cycle re-entry by inducing apoptosis (programmed cell death) when stimulation of the G1/S checkpoint is attempted. By these means, TF's prevent neurons from pursuing any proliferative or regenerative action (Figure 1).




Figure 1. Differentiating neurons exit the cell cycle into a terminal G0 state and are inhibited from entering S phase. Abnormal S phase entry stimulates neural apoptosis, preventing cell cycle progression and proliferation. Created using BioRender.com.

This paper examines how the specific regulations of cell cycle TFs in neurons inhibits their proliferation. Particularly, we consider how CDK inhibitors facilitate terminal G0 entry, and how these factors are regulated by BHLH, E2F, SMAD, FOXO1, SP1, c-MYC, p53, and Brn-3a TFs. We then review the mechanisms by which the G0 state is maintained, and how TFs E2F, FOXO1, C-JUN, and p53 facilitate apoptosis upon attempted G0 exit, securing neuron's anti-proliferation.

2 How TF's induce cell cycle arrest by producing CDK inhibitors

2.1 How CDK inhibition induces cell cycle arrest

CDKs, in all cell types, act as proliferative factors that progress the cell cycle. For cell cycle arrest to be achieved in neurons, CDKs 4/6 and 2 face inhibition at the G1/S phase checkpoint such that S phase entry is prevented. Two classes of cyclin kinase inhibitors (CKIs) that contribute to cell cycle arrest by repressing CDKs 4/6 and 2 are found in neurons. The first is the INK4 family, consisting of p15INK4b (p15), p16INK4a (p16), p18INK4c (p18), and p19INK4d (p19), which inhibit CDK 4/6 by impairing its interactions with type D cyclins. The second is the Cip/Kip family, including p21Cip1 (p21), p27Kip1 (p27), and p57kip2 (p57), which inhibit both CDK 4/6 and 2 by forming a ternary complex. The Cip/Kip family are the main regulators of cell cycle arrest in neurons, whereas INK4 proteins appear to play a larger role in G0 maintenance (discussed later). P27 is suspected to be the main CKI facilitating neural cell cycle arrest, however, p21 and p57 also contribute immensely to the process. As neurons proliferate and prepare for G0, all three Cip/Kip CKIs accumulate. Correspondingly, a decrease in CDK 4/6 and 2 activity results as cells near maturation. Upon

peak Cip/Kip expression, complete CDK inhibition occurs, blocking the G1/S transition and arresting the cell cycle. To facilitate G0 entry by means of CKI production, three major pathways dependent on cell cycle TFs must take place: the Cyclin D/RB induced pathway, the TGF β induced pathway, and the p53/Brn-3a pathway (3, 4).

2.2 The Cyclin D/ RB dependent pathways: utilizing TFs BHLH and E2F

The first TF-dependent neural G0 pathway is stimulated by a rise of cyclin D1. In proliferating cells, cyclin D1 rises in response to inducers of cell cycle progression and promotes the G1/S transition. In neurons, cyclin D1 elevates as a result of inducers of differentiation and cell cycle arrest. As cyclin D1 rises in neurons, CDK 4/6 experiences increased activity in the early stages of G0 entry. However, in order for cell cycle arrest to proceed, CDK 4/6 deviates from its proliferative function to instead stimulate production of refractory Cip/Kip CKIs. This negative feedback cycle represses activity of both CDKs 4/6 and 2 until a G0 status is achieved (3).

The Retinoblastoma (RB) family of proteins is responsible for initiating CKI transduction in a CDK-dependent manner. The RB family, including pRB, p130, and p107, regulate the cell cycle in all vertebrate cell types. In neurons, RB's role is specific to cell cycle arrest. RB's arresting function is mediated by cyclin D1. As cyclin D1 binds to and activates CDKs, RB proteins (major substrates of neural CDK 4/6) face hypophosphorylation their on serine (Ser) and threonine (Thr) residues and subsequent activation. Hypophosphorylated RB proteins can directly induce pro-G0 p27. However, their larger role is in regulating two distinct growth arrest pathways mediated by TFs BHLH and E2F (Figure 2) (3, 5).




Figure 2. The influx of cyclin D1 in G0-ready neurons binds to and hypophosphorylates RB proteins. RB then inhibits proliferative E2F and releases pro-G0 BHLH from inhibitory ID proteins. These actions lead to G0 entry. Created with BioRender.com.

The first RB-regulated mechanism of cell cycle arrest involves the basic helix-loop-helix (BHLH) family of TFs. In proliferating cells, BHLH members control cell cycle progression, cell lineage commitment, and cell differentiation. Specifically in neurons, they drive cells from a proliferative to a terminally differentiated and arrested state at the proper times and locations. Two distinct classes of BHLH proteins regulate neural cell cycle arrest. The first is proneural BHLH. Proneural BHLH promotes the onset of G0 by up-regulating CKI expression and repressing certain proliferative factors (Table 1). The second class of BHLH

consists of ID proteins. The ID family, consisting of Id1, Id2, Id3, and Id4, prevents G0 onset by working against proneural BHLH. ID proteins inhibit the rest of the BHLH family by withdrawing essential E proteins from BHLH factors. Neural cell cycle arrest requires a coordinated increase in proneural BHLH and decrease in ID proteins. Reduced ID activity is achieved in an RB-dependent pathway. As RB is hypophosphorylated upon G0 stimuli, it binds to and inhibits all ID members, allowing proneural BHLH to exert its anti-proliferative function (3, 6-15).

Table 1. Proneural BHLH types/functions. Proneural BHLH promote cell cycle arrest through induction of Cip/Kip CKIs and repression of proliferative genes. The NeuroD family appears to be the most significant proneural BHLH in regulating neuro-specific cell cycle arrest. (7-15).

BHLH Family	Atonal family	Nato family	Oligo family	NeuroD family	Neurogen family	Achate-scute family	Nsc1 family
Member proteins (vertebrates)	Math1 and Math5	Nato3	Beta3, Beta4, Olig1, Olig2, and Olig3	NeuroD, Ndrf, Math3, and Math2/nex	amphioxNgn, Ngn1, Ngn2, and Ngn3	Cash4, Mash1, Mash2, and Xash3	Nsc11 and Nsc12
Anti-proliferative function	Derepresses CKIs p27 and p57	Upregulates neurogen BHLH and represses proliferative HES proteins which inhibit p21 expression	Induces p27	Induces p27, p21, p57, and p16	Induces p27 and p57	Induces p21 and p27	Induces p21

A second RB-regulated G0 pathway involves TF E2F. The E2F family, consisting of E2F1-6, strongly activates transcription of several genes involved in differentiation and cell cycle progression. E2F1, E2F2, E2F3, and E2F6 act mainly as inducers of cell cycle progression, whereas E2F4 and E2F5 are more important during differentiation. In developing neurons, E2F1, E2F2, and E2F5 are detected. E2F1 and E2F2 are active preceding G0, allowing cells to grow and prepare for maturation. Upon differentiation, E2F5 expression increases as well. As differentiation proceeds, the corresponding onset of G0 stimuli dissipates E2F expression through RB hypophosphorylation. Hypophosphorylated RB proteins inhibit E2F-gene expression in two ways. The first is by directly binding to and blocking E2F's transactivation domain at its carboxyl terminus, inhibiting E2F gene activation. The second is by recruiting chromatin-modifying proteins such as histone deacetylases (HDACs), methyltransferases, and Polycomb group proteins, to E2F binding sites, making E2F genes epigenetically inaccessible to transcription altogether. E2F1 and E2F2 have a stronger affinity for pRB inhibition, whereas

E2F5 binds more strongly to p107 and p130. Upon G0 stimuli, rising levels of (p107/p130)/E2F5 complexes slow differentiation until a mature phenotype is concrete. Meanwhile, the onset of pRB/(E2F1/2) complexes initiates cell cycle arrest as proliferative genes are repressed. Combined with its activation of BHLH, these efforts conclude the RB-dependent cell cycle arrest pathways in neurons (3, 5, 16, 17).

2.3 The TGF β pathway: utilizing TFs SMAD, FOXO1, and c-MYC

A second TF-reliant neural cell cycle arrest pathway involves the stimulus of cytokine transforming growth factor beta (TGF β). TGF β signaling influences the activity of certain TFs to facilitate an array of biological processes in proliferating cells, including cell fate decisions, tissue patterning, and cell death. In neurons, TGF β elevates in cells ready to enter G0 and stimulates cell cycle arrest by interacting with TFs SMAD, SP1, FOXO1, and c-MYC to enhance pro-G0 CKI production (Figure 3) (6, 18).




Figure 3. Influxed TGFβ in G0-ready neurons activates SMADs 2,3, and 4, which directly induce CKI genes. SMADs 3/4 also interact with FOXO1 and SP1 to form complexes that induce the p21 gene and repress the MYC gene, inducing G0. Made with BioRender.com.

The main receptor of TGFβ signaling is the mothers against decapentaplegic (SMAD) family of TFs. In proliferating cells, SMADs have numerous functions and face type-dependent induction by various TGFβ ligands (Table 2). In neurons, R-SMADs 2/3 and Co-SMAD4 regulate G0 entry. In preparation for cell cycle arrest, TGFβ facilitates SMAD2/3/4

nuclear localization and phosphorylation. All three of these SMADs significantly induce the expression of CKIs p27 and p21. SMAD 3 and 4 also reduce expression of neural ID1 and ID2 and induce proneural BHLH factor neuroM. SMADs' efforts alone exert a strong anti-proliferative force on developing neurons (6, 18-27).

Table 2. SMAD family members and function. There are three subtypes of SMAD proteins: receptor-regulated SMADs (R-Smads), common partner SMADs (Co-SMADs), and inhibitory SMADs (I- SMADs). The BMP pathway and TGF β /activin responses activate SMAD-phosphorylation membrane receptor serine/threonine kinases (receptors type I and II). TGF β mediated activation of SMADs increases their affinity for a common SMAD (SMAD4), an essential component for the assembly of transcriptional complexes and for the generation of specific SMAD responses. (20-27)

SMAD Family	SMAD1	SMAD2	SMAD 3	SMAD4	SMAD5	SMAD6	SMAD7	SMAD8/9
Method of activation	BMP pathway	TGF β /activin responses	TGF β /activin responses	Formation of a transcriptional complex with other SMAD family members	BMP pathway	BMP pathway and TGF β /activin responses	TGF β R1	BMP pathway
Subtype	R-SMAD	R-SMAD	R-SMAD	Co-SMAD	R- SMAD	I- SMAD	I- SMAD	R- SMAD
Proliferative cell function	Cell growth, apoptosis, morphogenesis, development and immune responses	Cell proliferation, apoptosis, and differentiation	Regulating gene activity and cell proliferation	Shuttles other SMAD family members between the nucleus and cytoplasm	Angiogenesis	BMP signal inhibitor	General TGF β signal inhibitor	BMP/TGF β signal transducer
Neural function	Neuron development (pre-G0)	Cell cycle arrest	Cell cycle arrest	Cell cycle arrest	Neuron development (pre-G0)	Differentiation	Neuron proliferation	Neuron development (pre-G0)

However, SMADs 3 and 4 also interact with forkhead box protein O1 (FOXO1) and SP1 TFs to further induce cell cycle arrest. In proliferating cells, FOXO1 and SP1 act as tumor suppressors and maintain organismal longevity. In neurons, these factors modulate cell cycle arrest. TGF β initiates the nuclear translocation of FOXO1 and SP1 proteins and forms SMAD3/SMAD4/FOXO1 and SMAD3/SMAD4/SP1 complexes. TGF β then recruits these complexes to multiple sites of the p21 promoter, where they activate p21 expression and facilitate G0 entry as such. (18, 19).

SMAD3 /SMAD4 /FOXO1 and SMAD3 /SMAD4 /SP1 complexes further contribute to cell cycle arrest by repressing c-MYC. The myelocytomatosis oncogene (MYC) family of

TFs regulates cell proliferation and differentiation in multiple cell types, including neurons. c-MYC proteins promote cellular growth and proliferation during early neural development by inhibiting CKIs, however, their down-regulation is essential for differentiation and cell cycle arrest. TGF β recruits SMAD3 /SMAD4 /FOXO1 and SMAD3 /SMAD4 /SP1 complexes to the c-MYC promoter, which inhibit c-MYC transcription. TGF β then administers c-MYC cytoplasmic localization, removing all existing c-MYC factors from the nucleus. Complete annihilation of c-MYC sufficiently de-represses the p21 promoter such that it can initiate G0 entry. There is rising evidence that c-MYC inhibition may also de-repress the p15 and p27 CKI promoters, its repression being potentially even more significant to G0 entry (3, 18).

Combined, as TGF β activates SMAD2/3/4, FOXO1, and SP1 and represses c-MYC, cell cycle arrest is induced by p21, p27, and the pathways involving proneural BHLH factor neuroM.

2.4 The p53/Brn-3a TF pathway

A third and final pathway crucial to neural cell cycle arrest involves TFs p53 and Brn-3a. P53 is most well-known for its pro-apoptotic function in most cell types, including neurons. However, through differential regulation, p53 also promotes cell cycle arrest and differentiation in neural progenitors. The difference between p53's pro-apoptotic phenotype (discussed later) and cell cycle arrest phenotype relies heavily on neuro-specific post-translational modifications (PTM). p53 has highly variable amino and carboxyl termini, which allow it to face a variety of PTMs, including phosphorylation, acetylation, sumoylation, neddylation, and ubiquitination. Depending on which PTM's p53 receives, its

protein-protein interactions and subsequent function differ. P53's cell cycle arrest phenotype is mediated primarily by mechanisms of acetalization by histone acetyltransferases (HATs) (Figure 4). P53 acetylation occurs in response to a variety of G0 events including TGF β signaling, RB hypophosphorylation, and the stimuli associated with various steps of neural differentiation. These modifications prevent p53 from binding to pro-apoptotic genes and allow it to activate the p21 promoter, inducing G0 entry. However, p53's shift from a pro-apoptotic phenotype to a pro-G0 phenotype also relies on the neuro-specific TF Brn-3a. Upon differentiation, p53 and Brn-3a form a complex that inhibits p53 from activating pro-apoptotic genes and increases its affinity for the p21 promoter. Combined, PTMs and Brn-3a help p53 adopt pro-G0 functionality. P53 then regulates G0 entry by activating p21 transcription, inhibiting proliferative MYC transcription, and activating the growth arrest and DNA damage (GADD45) gene (inductive of p21 and p27) (3, 18, 28-30).




Figure 4. Mechanisms of p53 acetalization to induce G0. P53 acetylation at its carboxyl terminus regulates its protein stability, allows it to induce pro-G0 genes, and inhibits its ability to bind to pro-apoptotic genes. Created with BioRender.com.

2.5 Summary of TF-dependent neuron cell cycle arrest

Cell cycle arrest is achieved by inhibition of CDKs through production of CKIs. In neurons, this process is highly regulated by several TF-dependent pathways. The discussed mechanisms of TF-dependent neural cell cycle arrest can be summed up as follows: upon the stimulus of cyclin D1 in developed neurons ready to enter G0, CDK 4/6 is initially activated and hypophosphorylates RB proteins. Hypophosphorylated RB inhibits proliferative ID proteins to promote activity of pro-G0 BHLH TFs while also directly repressing proliferative E2F TFs.

Meanwhile, the onset of TGF β in neurons prepared to enter G0 induces TF SMAD-dependent cell cycle arrest. TGF β activated SMAD proteins promote expression of proneural BHLH and CKIs. However, SMADs also interact with TFs FOXO1 and SP1 to induce CKI expression and inhibit proliferative c-MYC TFs. Finally, both hypophosphorylated RB and TGF β , alongside other G0 stimuli, activate TF p53. P53 interacts with TF Brn-3a to further induce CKI expression. As CKIs rise to substantial enough levels through the pathways discussed, they inhibit the CDKs which induced their very onset. CDK inhibition blocks expression of proliferative S phase genes, leaving the cell cycle arrested in G0.

3 How TFs induce neural apoptosis upon attempted cell cycle re-entry

3.1 G0 maintenance/ Apoptosis upon cell cycle re-entry

After initial withdrawal from the cell cycle, the G0 state is maintained CKIs, necdin proteins, and nerve growth factors (NGF). In these components' absence, neural cell cycle re-entry is attempted but thwarted by a lack of proper S phase machinery. To prevent abnormal and potentially cancerous S phase onset, neurons have developed TF-dependent pro-apoptotic pathways in response to attempted proliferation. Discussed are the mechanisms by which CKIs, necdin, and NGF contribute to G0 maintenance, and how their withdrawal triggers neural apoptosis (16).

CKIs, by inhibiting CDKs, are essential to G0 maintenance. Cip/Kip CKIs p21, p27, and p57 are upregulated preceding cell cycle arrest and continue to be expressed throughout the G0 lifespan. Neural INK4 CKIs p15, p16, and p19 also face increased expression upon G0 entry (Figure 5). Collectively, these two classes of CKIs maintain neuronal mitotic quiescence by inhibiting CDK 4/6 and 2. Upon Cip/Kip and INK4 CKI withdrawal, CDK-derepression-dependent apoptosis is triggered. Specifically, CDK 4/6 plays the largest role in regulating several neural apoptosis pathways (3, 5, 16, 19).




Figure 5. CKI expression in neurons. P18 is the only CKI expressed during pre-G0 development. Cip/ Kip CKIs p21, p27, and p57 rise before G0 entry to facilitate it's onset. Upon G0 entry, p18 diminishes and is replaced with p19, p16, and p15.

The neuron-specific protein necdin is also essential to G0 maintenance by functionally substituting for RB proteins pRB and p107 after their degradation post-differentiation (Figure 6). Necdin fills the essential niche of these RB members by binding to the transactivation domain of proliferative E2F1 and repressing E2F-dependent transcription. While RB and necdin are functionally similar, the two are structurally divergent (Figure 7). Structural

differences allow necdin to also bind to the amino-terminal transactivation domain of p53 and inhibit p53-dependent transcription. It does not counteract p53-induced cell cycle arrest but does repress p53-dependent apoptosis, further contributing to the maintenance of the postmitotic state of neurons. In necdin's absence, both p53 and E2F1's pro-apoptotic functions are activated and cell death ensues (16, 31, 32).




Figure 6. RB/Necdin expression in neurons. Upon G0 entry, RB protein expression levels rise. During neural terminal differentiation, RB members pRB and p107 are downregulated and replaced with necdin, while p130 expression remains high.




Figure 7. RB1 vs. Necdin structural comparison. Necdin has 325 amino acids whereas RB1 has 921. It's reduced size is also what allows necdin to bind to p53. (31, 32)

Finally, NGF is also vital to the maintenance of the G0 state because it activates essential survival pathways. NGF promotes pathways that allow cells to thrive in G0 and represses pro-apoptotic pathways and molecules such as the p75 neurotrophin receptor. Deprivation of NGF results in direct de-repression of these pro-apoptotic machinery. NGF's absence also triggers CDK-dependent apoptosis by promoting the expression of cyclin D1. Like CKI withdrawal, this method of apoptosis relies heavily upon CDK 4/6 (5, 19, 33, 34).

Combined, the presence of CKIs, necdin, and NGF helps neurons maintain a stable G0 state. In these factors' absence, pro-apoptotic pathways which rely on CDK 4/6 and cell cycle TFs are activated. Here, we discuss how CDK 4/6 interacts with RB proteins to trigger multiple E2F1-dependent pro-apoptotic pathways. Specifically, we observe E2F1's interactions with FOXO1, C-JUN, and p53 TFs, which collectively facilitate neural cell death.

3.2 Interactions between CDK4/6 and RB: spurring a pro-apoptotic excess of E2F1

The majority of TF-dependent pro-apoptotic pathways in neurons also rely on CDK 4/6. In cells experiencing a temporary G0 state, CDK 4/6 activation causes cells to re-enter the cell cycle and proceed to S phase through modulation of proliferative genes. However, since S phase entry is recognized as malignant in neurons, neural CDK 4/6 signals have instead evolved to facilitate apoptosis through RB-mediated mechanisms. CDK 4/6's interactions with RB differ upon apoptotic stimuli from those witnessed upon cell cycle arrest (Table 3). Ultimately, CDK 4/6 hyperphosphorylates and subsequently inactivates p130, the only RB member remaining post-G0 entry. This initiates neural apoptosis through p130's interactions with E2F1 (Figure 8) (5, 16, 19).

Table 3. CDK interactions with RB in cell cycle arrest vs. apoptosis in neurons. During cell cycle arrest CDKs hypophosphorylate and subsequently activate RBs. During apoptosis, CDKs hyperphosphorylate and inactivate RBs. All three RB members, pRB, p130, and p107, are prevalent in the mechanisms regulating cell cycle arrest. However, upon G0 entry, neural pRB and p107 are downregulated and replaced by necdin. Correspondingly, neither pRB nor p107 yield any regulative effect regarding neural apoptosis upon cell cycle re-entry, whereas p130 (remaining upregulated) controls massive strain-dependent neuronal death.

	Cell cycle arrest	Apoptosis
CDKs initiating RB interaction	CDKs 4/6 and 2	CDK 4/6
RB's facing phosphorylative modulation	pRB, p130, and p107	p130
CDK action upon RB	hypophosphorylation (activation)	hyperphosphorylation (inactivation)




Figure 8. Deprivation of essential G0 factors causes an influx of CDK4/6. CDK4/6 de-represses the E2F1 inhibitory complex by hyperphosphorylating p130, causing E2F1 overexpression. Free E2F1 activates TF-dependent apoptosis. Created with BioRender.com.

Upon G0 entry, E2F1 is degraded by various post-mitotic mechanisms (Figure 9) such that its activity is negligible in G0 neurons. Hyperphosphorylated p130 reverses E2F1 inhibition in cells destined for apoptosis. There are two major consequences of CDK-mediated hyperphosphorylation of p130. The first is the release of p130 from the E2F1 transactivation domain, promoting E2F1-dependent gene induction. The second is the dissolution of E2F1-chromatin modifying complex tethered to p130 (Figure 10), promoting transcriptional de-repression of E2F1-regulated genes. It is this latter mechanism of de-repression that facilitates E2F1-mediated apoptosis. In other words, it is not the expression of the E2F-

modulated genes themselves that transduces E2F1-regulated neural apoptosis, but the fact that the inhibitory complex blocking E2F1 activity is absent. Loss of the neclin E2F-inhibitory complex is another mechanism by which this de-repression could occur. In either case, E2F1 de-repression transduces an over-amplified positive feedback cycle of E2F1 production. As E2F1 is overexpressed beyond the capacity of DNA binding sites, an excess accumulates in the nucleus. This free E2F1 then activates multiple TF-dependent pro-apoptotic pathways, including the CDK1/FOXO1 pathway, the JNK/C-JUN pathway, and the p53 pathway (5, 16, 35).




Figure 9. Mechanisms of post-mitotic E2F1 degradation. After the initial increase of E2F1 during neural differentiation and G0 entry, E2F1 expression and activity decreases to undetectable levels in post mitotic neurons. Created with BioRender.com.




Figure 10. If RB binds to DNA-bound E2F, it forms a chromatin modifying complex that represses transcription of target genes. RB hyperphosphorylation dissipates the chromatin modifying complex and derepresses E2F regulated DNA. Created with BioRender.com.

3.3 FOXO1 pro-apoptotic pathway: facing induction by E2F1 Interactions with CDK1

The first TF-dependent cell death pathway detonated by free E2F1 first involves CDK1. CDK1 is associated with neural cell death triggered by membrane activity deprivation and various neurodegenerative diseases such as Alzheimer's, frontotemporal dementia, and progressive supranuclear palsy. Excess free E2F1 regulates CDK1 in all of these contexts by activating the CDK1 promoter.

Activated CDK1 regulates apoptosis in two ways. The first is by directly phosphorylating and activating the pro-apoptotic BAD gene. CDK1 phosphorylates Bcl-2 family member BCL2 Associated Agonist Of Cell Death (BAD) at its Ser128 site, dissociating BAD from inhibitory 14-3-3 proteins and activating its transcriptional activity. The second is by inducing the TF FOXO1. While in non-neuronal cells, FOXOs initiate transcription of genes involved in DNA damage repair, protection against reactive oxygen species, and maintenance of organismal longevity, neural FOXO1 facilitates cell death. CDK1 binds to and phosphorylates FOXO1 on Ser249 in a

mechanism resemblant of its activation of the BAD gene. Upon phosphorylation, FOXO1 faces nuclear accumulation and subsequent transcriptional activity, activating the pro-apoptotic Bcl-2 Interacting Mediator of cell death (BIM) gene. BIM gene induction, with the help of the BAD gene, is ultimately what facilitates apoptosis in a CDK1 and FOXO1 context (16, 19, 34).

3.4 C-JUN pro-apoptotic pathway: facing induction by E2F1 Interactions with GCK

The second E2F1-mediated pro-apoptotic pathway involves transduction of the C-JUN TF. E2F1 directly activates the MAP4K germinal center kinase (GCK). Transcriptional induction of GCK induces a phosphorylation cascade (Figure 11) that ultimately activates the JNK (Jun N-terminal kinases) family of MAP kinases. The JNK family consists of JNK1, JNK2 and JNK3. All three JNKs phosphorylate and activate the C-JUN protein of the activator protein-1 (AP-1) TF. In most proliferating cells, C-JUN functions in preventing apoptosis. However, in neurons, it does the exact opposite. C-JUN activation by JNKs causes neural cell death by activating the pro-apoptotic BIM,

PUMA, and dp5/hrk family genes. These efforts combined facilitate C-JUN-induced neural apoptosis (34, 36-38).




Figure 11. E2F1 phosphorylation cascade. E2F1 activates the MAP4K GCK. MAP4K then phosphorylates MAP3Ks, which activate the MAP2K isoforms MKK4 and MKK7. MKK4 and MKK7 phosphorylate JNKs. Finally, JNKs induce c-Jun. Created with BioRender.com.

3.5 p53 pro-apoptotic pathway: directly modulated by free E2F1

A third and final TF-dependent neural apoptosis pathway mediated by free E2F1 involves the TF p53. p53 is notorious for its pro-apoptotic function in many cell species in response to a plethora of stimuli. In neurons, its activity is observed in response to NGF withdrawal, CKI inhibition, DNA damage, and a number of neurodegenerative disorders such as Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. P53 has a heightened relevance to neuro-specific apoptosis over other TFs. Overexpression of p53 alone can spur cell death even in the presence of NGF, as all other pro-apoptotic pathways remain dormant. Furthermore, apoptosis is prevented in p53 deficient cells even in the absence of NGF and activation of all other pro-apoptotic pathways. Conclusively,

p53 is a determinant factor in whether neurons will live or die upon G0 exit.

P53's pro-apoptotic function requires highly specific PTMs to distinguish it from its cell cycle arrest pathways. Specifically, to induce its pro-apoptotic phenotype, p53 faces several rounds of phosphorylation on its amino terminal region. These modifications induce p53's nuclear localization, activation of specific pro-apoptotic genes, and inhibition of proliferative genes (Figure 12). Specific phosphorylation of the Ser46 site by free E2F1 also inhibits p53's ability to bind to the p21 promoter. This action prevents the counteractive p53 cell cycle arrest pathway that would otherwise prevent p53-mediated apoptosis. P53 PTMs modulated by other TF pathways are also of note. Specifically, the pro-apoptotic JNK/C-JUN pathway mediates Thr81 phosphorylation on the p53

amino terminal. This action allows p53 to activate the pro-apoptotic Bcl-2 Associated X-protein (BAX) gene. The dissolution of necdin proteins from the p53 complex is another neuro-specific PTM required for p53 apoptotic

regulation. Necdin proteins inhibit p53 at its amino terminal transactivation domain. A pathway outlining the release of necdin from p53 required for apoptosis has yet to be outlined. (5, 16, 28, 29, 33, 37, 39, 40-44).

Site of phosphorylation	Ser 15	Ser 20	Ser 33	Ser 46	Ser366	Ser392	Thr 18	Thr 81	Thr 304	Thr 77	Thr 387
Mechanism of phosphorylation	MAPK-p38 signaling	PLK3 and Chk2	MAPK-p38 signaling	Free E2f1, MAPK-p38 signaling, ATM signaling	CHK1	CK2	MAPK-p38 signaling and VRK1/2	JNK/C-Jun activity	LRRK2	LRRK2	CHK1
Pro-apoptotic consequence of phosphorylation	Prevents p53 nuclear export and triggers phosphorylation cascade of other p53 C/N terminal sites	Prevents p53 nuclear export and activates pro-apoptotic Fas, PUMA, IGFBP-3, Noxa, Bax and PIG3 genes	*	Induces p53API1 and inhibits binding to P21 promoter	Induces proapoptotic BAX gene	*	Prevents p53 nuclear export and activates pro-apoptotic Fas, PUMA, IGFBP-3, Noxa, and PIG3 genes	Induces pro-apoptotic BAX gene	*	*	Induces proapoptotic BAX gene

* The precise effects of the phosphorylation of this target site are unclear.
 * P53 is also known to activate pro-apoptotic genes Bid, Bad, APAF1, and p73 in neurons, as well as repress proliferative genes Bcl-2, Bcl-xL, and Mcl-1. The PTMs allowing P53 to modulate these sites are unclear.




Figure 12. Mechanisms of p53 phosphorylation to induce apoptosis. P53's pro-apoptotic phenotype is mediated primary by various rounds of phosphorylation on its N and C terminals. Created with BioRender.com. (37, 39, 40, 41, 42, 43, 44)

3.6 Summary of TF-dependent neuron apoptosis

When neurons attempt to exit G0, multiple pro-apoptotic pathways involving cell cycle TFs are activated. All of the pathways we discuss rely on the activation and de-repression of CDKs 4/6 by various apoptotic stimuli. These CDKs hyperphosphorylate RB protein p130, which de-represses the E2F1 gene by releasing its attached inhibitory complex. De-repression of E2F1 corresponds with a nuclear excess of free E2F1. Free E2F1 triggers three main TF-dependent pathways. The first involves E2F1's activation of CDK1. CDK1 directly phosphorylates the FOXO1 TF. FOXO1 then regulates the pro-apoptotic BIM gene, resulting in cell death. The second E2F1-dependent pathway relies on its activation of GCK which, through a phosphorylation cascade, ultimately activates TF C-JUN. C-JUN is a regulator similar to FOXO1 in its transcriptional activation of BIM, but also functions in promoting many other pro-apoptotic genes. Finally, E2F1 overexpression directly activates

transcription factor p53. The group of pathways promoted by p53 is vast and likely the main stimulus of TF-induced neural apoptosis. Combined, these TF pathways facilitate cell death in neurons upon attempted proliferation, preventing their re-entry into the cell cycle.

4 Perspectives

4.1 Addressing differences in the CNS and PNS antiproliferation

The TF-dependent pathways regulating G0-entry and related anti-proliferation are identical in the CNS and peripheral nervous systems (PNS), seeing as both central and peripheral neurons are derived from like precursor cells. This being said, recent studies have unveiled post-maturational proliferative differences in the PNS and CNS when cells attempt to exit G0. The CNS, upon attempted proliferation, commits apoptosis via the TF-dependent pathways discussed in this review. Contrarily, the PNS, under certain conditions, appears to occasionally avert these pathways to

successfully proliferate without committing apoptosis. This would initially appear to contradict the TF-dependent neural anti-proliferation hypothesis because the CNS and PNS possess the same pro-apoptotic pathways. However, upon further investigation, the divergent ability of PNS neurons to occasionally exit the cell cycle emanates in the presence of Bcl-2 protein in adult PNS neurons which deems pro-apoptotic TFs ineffective. (45).

The Bcl-2 protein is a major inhibitor of apoptosis, notably through its interactions with TFs and related genes. Specifically, it binds to BAX, BAK, BIK, BID, BAD, BIM, and PUMA, blocking FOXO-1, C-JUN, and P53 induced apoptosis. (46,47)

This inhibitory property of Bcl-2 is essential to the survival of pre-G0 neurons of both the CNS and PNS. However, once CNS neurons enter G0, Bcl-2 typically diminishes. PNS neurons, in contrast, retain elevated levels of Bcl-2 even after they have entered G0. This allows them to avert TF-induced apoptosis when they re-enter the cell cycle upon various stimuli. (47,48).

This application of Bcl-2 in CNS neurons remains unexplored. However, it could yield big advances in clinical neurology and should be further researched to test its possibilities in vitro and vivo.

4.2 Addressing potentially unreliable cases of CNS proliferation

In the growing field of neuroscience, rare in vitro cases of CNS proliferation have been observed. These cases defy the TF-dependent apoptosis which is inevitable upon G0 exit. However, these cases are faulty and have highlighted the unreliability of standard neurogenesis tracking methods. (49).

Historically, scientists have used thymine to track neurogenesis. However, in recent decades, many researchers have transitioned to the thymidine analog bromodeoxyuridine (BRDU) as a tracking agent due to its efficiency in lab compared over regular thymine. It was long believed that BRDU, since it showed the reactivation of key cell cycle molecules, denoted neural entry into the S phase. Although recently BRDU's efficacy has been questioned. (49).

Several problems have been found with BRDU as a neurogenesis tracker. First, because it works by incorporating itself into the host genome, there is rising concern that BRDU could potentially alter DNA expression and thus negatively influence cell cycle kinetics and viability. This could be one potential explanation for the false positive results witnessed upon alleged cases of neural proliferation. Another concern lies in the potential of BRDU "diluting" after several rounds of cell replication when it is initially incorporated into neural stem cells, making its presence hard to detect and interpret. This too could yield unviable results in lab. Finally, the most compelling evidence backing the unreliability of BRDU suggests that BRDU is not a marker of neurogenesis at all but rather an early marker of neural death. (49).

BRDU indicates re-expression of cell cycle proteins. This would initially seem to indicate proliferation. However, as aforementioned, the reactivation of proteins such as CDKS activates TFs that ensue neural death. This was eventually evident in lab when neurons began to degrade and die after they were allegedly proliferating. These findings were significant because they gave further evidence to support a TF-dependent neural anti-proliferation

hypothesis when neurons began to die after expressing seemingly proliferative factors. (50). Combined, this evidence refutes the reliability of BRDU as a marker of neurogenesis and deems the alleged cases of neural proliferation faulty. (50)

While BRDU may not be a completely reliable marker of neurogenesis, it has potential application as an early predictor of neural disease. From the time that BRDU shows reactivation of cell cycle proteins, cell death can be predicted in the months to follow. Harnessing this application of BRDU in vivo could allow physicians to confirm neurodegenerative disease in its incubation period rather than post-mortem as they are often diagnosed. This practical application of BRDU could yield great advances in clinical neurology by giving physicians the chance to administer medication before the arrival of symptoms in patients suffering from neurodegenerative disease, increasing their chances of stalling, or even completely eliminating the disease before it is in full force. (50).

4.3 TF application in marking specific instances of neurodegenerative disease

Alongside BRDU, TFs themselves have a growing application in marking specific instances of neurodegenerative disease.

TFs and other cell cycle proteins offer several benefits over BRDU leading to their increased usage in lab as neurodegenerative markers. First, unlike BRDU which potentially dilutes after several rounds of replication, TFs are always prevalent in cells. Their activity can be consistently monitored and results consistently read. TFs also have a wider application in studies where BRDU cannot be used, such as those in dead human tissues or wild animal populations. Finally, TFs offer the benefit of

specificity by showing the specific pathway that neurons are using to exit the cell cycle. (50, 51) By these means, TFs have the potential to identify specific diseases based on their associated TF/cell cycle protein pathways. Marking potentially diseased cells before they commit apoptosis could give researchers further insight as to how specific neurodegenerative diseases cause cell death. This would give the opportunity to develop more targeted medicine and other preventative measures to potentially prevent these diseases in the future. In vivo, TFs could be used likewise as helpful biohazard markers to help clinicians diagnose and target specific neurodegenerative diseases before the arrival of symptoms. (50, 51)

These potential applications of TFs both in vivo and vitro should yield further research and investigation in the future and give hope for a new generation of medicine in which neurodegenerative disease is controllable or even completely preventable.

4.4 Potential application of partial cell cycle re-entry

Thus far, this review has focused on the degenerative aspects of cell cycle re-entry. However, it must be considered that in recent academic literature, potential neuroprotective functions of “partial” cell cycle re-entry have been discovered. Mainly, scientists are now considering the possibility of neurons being able to exit G0 and enter a non-degenerative variant cell cycle upon extensive damage or degradation. This variant cell cycle involves neurons going through repetitive S and G2 without entering M, allowing them to replicate their DNA without dividing. This results in a state of polyploidy which appears to have many benefits in neurons. Polyploid cells are bigger and more resistant to DNA damage because of their genome redundancy. They also have an

increased cell signaling capacity, leading to more efficient metabolic functionality. Finally, in non-neural cells, polyploidy often allows for cellular healing upon damage. It is speculative that the same might be true for neurons. More research needs to be done to confirm this hypothesis. (35, 52)

This process of partial cell cycle re-entry that results in polyploid neurons is regulated by the same TFs which normally ensue cellular death upon activation in G0. Specifically, E2F, P27, and other members of the P53 family have been found to regulate neural polyploidism in vivo and vitro. Why then, does this process not lead to neural death like complete cell cycle exit does? The answer is still unknown. However, neural polyploidy highlights the importance of mitotic pathways in regulating neural cell death. When mitosis is attempted, apoptosis is imminent. However, when it is left out of the picture, neurons remain functional. More research needs to be done on this front to confirm the exact role of mitotic pathways in neural death and how they relate to the roles of TFs in spurring apoptosis. (35, 52)

5 Conclusion

The inhibition of neural proliferation requires a complex collection of pathways that arrest cells in G0, maintain a stable G0 state, and prevent cell cycle re-entry by means of apoptosis. Cell cycle TFs contribute to all of these processes by functioning in a neuron-specific anti-proliferative manner. Regarding the initial entry into G0 by CDK inhibition through CKI production, three major TF-dependent pathways emerge. The first involves hypophosphorylated RB proteins which induce the activity of proneural BHLH and repress proliferative E2F. The second involves the stimulus of TGF β , which induces the activity of pro-G0 SMAD, FOXO1, and SP1 while repressing proliferative

c-MYC. The third pathway involves activation of pro-g0 p53 and Brn-3a. Combined, these efforts facilitate entry into the G0 phase which is maintained by essential CKIs, necdin proteins, and NGF. Upon deprivation of these elements, cell cycle progression is attempted but impeded by apoptotic pathways that facilitate cell death before any significant proliferative progress can be made. The TF-dependent pathways regulating this process all rely on the hyperphosphorylation of RB and subsequent overexpression of E2F1. The presence of excess free E2F1 activates three main pathways of relevance. The first involves E2F1 activation of CDK1 which induces pro-apoptotic FOXO1 TFs. The second entails E2F1 induction of GSK which ultimately facilitates the pro-apoptotic function of the C-JUN TF. Finally, the last involves E2F1's activation of pro-apoptotic p53 TFs, which appear to play the greatest role in facilitating TF-dependent cell death.

These efforts of neural cell cycle transcription factors induce cell cycle arrest and prevent its re-entry. This keeps neurons in a terminally unreplicable state that inhibits them from reproducing or repairing upon damage, disease, or degradation with age. The malignant consequences of this system are especially evident in the cases of significant injury, DNA damage, or degenerative disease. It remains speculative why neurons, in all their importance to organismal functionality, have evolved to possess such vulnerability to these threats compared to other cells. However, a growing body of research is unveiling potential solutions to neurons' anti-proliferation, giving hope for a future in which their aversion to replication can be diluted or potentially even annihilated.

Acknowledgements

I would like to thank Danielle Clark, 5th year PhD student from the immunology department

at Duke University, for acting as my mentor and program and team for giving me this guiding me through the writing process. I would opportunity and helping me along the way. also like to acknowledge the Polygence

Abbreviations

BHLH – Basic helix–loop–helix, BRDU – Bromodeoxyuridine, CDK – Cyclin dependent kinase, CKI – Cyclin dependent kinase inhibitor, CNS – Central nervous system, FOXO – Forkhead box protein O, HDAC – Histone deacetylases, JNK – Jun N-terminal kinase, MYC – Myelocytomatosis oncogene, NGF – Nerve growth factor, PNS – Peripheral nervous system, PTM – Post-translational modification, P15 – p15INK4b, P16 – p16INK4a, P18 – p18INK4c, P19 – p19INK4d, P21 – p21Cip1, P27 – p27Kip1, P57 – p57kip2, RB – Retinoblastoma, Ser – Serine, SMAD – Mothers against decapentaplegic, TF – Transcription Factor, Thr – Threonine, TGFβ – Transforming growth factor-beta

References

1. Alberts, B., Johnson, A., and Lewis, J. (2002). An Overview of the Cell Cycle. Molecular Biology of the Cell, 4. <https://www.ncbi.nlm.nih.gov/books/NBK26869/>
2. Bertoli, C., Skotheim, J. M., and Bruin, R. A. M. (2015). Control of Cell Cycle Transcription during G1 and S Phases. Nature Reviews Molecular Cell Biology, 14(8), 518–528. <https://doi.org/10.1038%2Fnmr3629>
3. Galderisi, U., Paolo Jori, F., and Giordano, A. (2003). Cell Cycle Regulation and Neural Differentiation. Oncogene, 22, 5208–5219. https://dpl6hyzg28thp.cloudfront.net/media/cell_cycle_regulation_and_neural_differentiation_2003.pdf
4. Creff, J., and Besson, A. (2020). Functional Versatility of the CDK Inhibitor p57Kip2. Cell Growth and Division, 8. <https://doi.org/10.3389/fcell.2020.584590>
5. Greene, L. A., Biswas, S. C., and Liu, D. X. (2003). Cell cycle molecules and vertebrate neuron death: E2F at the hub. Cell Death and Differentiation, 11, 49–60. <https://doi.org/10.1038/sj.cdd.4401341>
6. García-Campmany, L., and Martí, E. (2007). The TGFbeta intracellular effector Smad3 regulates neuronal differentiation and cell fate specification in the developing spinal cord. Development, 134(1), 65–75. <https://doi.org/10.1242/dev.02702>
7. Ochocinska, M. J., and Hitchcock, P. F. (2009). NeuroD regulates proliferation of photoreceptor progenitors in the retina of the zebrafish. Mechanisms of development, 126(3-4), 128–141. <https://doi.org/10.1016/j.mod.2008.11.009>

8. Uittenbogaard, M., and Chiaramello, A. (2006). The basic helix-loop-helix transcription factor Nex-1/Math-2 promotes neuronal survival of PC12 cells by modulating the dynamic expression of anti-apoptotic and cell cycle regulators. *Journal of Neurochemistry*, 92(3), 585–596.
<https://doi.org/10.1111%2Fj.1471-4159.2004.02886.x>
9. Vandussen, K. L., and Samuelson, L. C. Mouse atonal homolog 1 directs intestinal progenitors to secretory cell rather than absorptive cell fate. *Developmental Biology*, 346(2), 215–223.
<https://doi.org/10.1016/j.ydbio.2010.07.026>
10. Skaggs, K., Martin, D. M., and Novitch, B. G. (2011). Regulation of spinal interneuron development by the Olig-related protein Bhlhb5 and Notch signaling. *Development*, 138 (15), 3199–3211.
<https://doi.org/10.1242/dev.057281>
11. Lacomme, M., Liaubet, L., Pituello, F., Bel-Vialar, S. (2012). NEUROG2 Drives Cell Cycle Exit of Neuronal Precursors by Specifically Repressing a Subset of Cyclins Acting at the G1 and S Phases of the Cell Cycle. *Molecular Cell Biology*, 32(13), 2596–2607.
<https://doi.org/10.1128%2FMCB.06745-11>
12. Somnay, Y. R., Zarebczan Dull, B., Eide, J., Jaskula-Sztul, R., and Chen, H. (2015). Chrysin suppresses the achaete-scute complex-like1 and alters the neuroendocrine phenotype of carcinoids. *Cancer Gene Therapy*, 22(10), 496–505. <https://doi.org/10.1038%2Fcgt.2015.49>
13. Bertrand, N., Castro, D. S., Guillemot, F. (2002). *Nature Reviews*, 3, 517–529.
<http://www.bio.brandeis.edu/classes/nbio143/Papers/Neurogenesis/Bertrandetal.pdf>
14. Lécuyer, E., Larivière, S., Sincennes, M., Haman, A., Lahlil, R., Todorova, M., Tremblay, M., Wilkes, B. C., Hoang, T. (2007). Protein Stability and Transcription Factor Complex Assembly Determined by the SCL-LMO2 Interaction. *Journal of Biological Chemistry*, 282(46), 33649–33658. <https://doi.org/10.1074/jbc.M703939200>
15. Yan, C. H., Levesque, M., Claxton, S., Johnson, R. L., and Ang, S. (2011). Lmx1a and Lmx1b Function Cooperatively to Regulate Proliferation, Specification, and Differentiation of Midbrain Dopaminergic Progenitors. *Journal of Neuroscience*, 31 (35), 12413–12425.
<https://doi.org/10.1523/JNEUROSCI.1077-11.2011>
16. Yoshikawa, K. (2000). Cell cycle regulators in neural stem cells and postmitotic neurons. *Neuroscience Research*, 37, 1–14.
https://dpl6hyzg28thp.cloudfront.net/media/cell_cycle_regulators_in_neurons.pdf
17. Giangrande, P. H., Zhu, W., Schlisio, S., Sun, X., Mori, S., Gaubatz, S., and Nevins, J. R. (2004). A role for E2F6 in distinguishing G1/S- and G2/M-specific transcription. *Genes and Development*, 18, 2941–2951, <http://www.genesdev.org/cgi/doi/10.1101/gad.1239304>

18. Palazuelos, J., Kilngener, M., and Aguirre, A. (2014). TGF Signaling Regulates the Timing of CNS Myelination by Modulating Oligodendrocyte Progenitor Cell Cycle Exit through SMAD3/4/FoxO1/Sp1. *The Journal of Neuroscience*, 34(23), 7917–7930.
<https://www.jneurosci.org/content/jneuro/34/23/7917.full.pdf>
19. Palazuelos, J., Kilngener, M., and Aguirre, A. (2014). TGF Signaling Regulates the Timing of CNS Myelination by Modulating Oligodendrocyte Progenitor Cell Cycle Exit through SMAD3/4/FoxO1/Sp1. *The Journal of Neuroscience*, 34(23), 7917–7930.
<https://www.jneurosci.org/content/jneuro/34/23/7917.full.pdf>
20. Kim, A. H., and Bonni A. (2008). *Cell Cycle*, 7(24), 3819–3822.
<https://doi.org/10.4161/cc.7.24.7215>
21. Liang, YY., Brunicardi, F. and Lin, X. (2009). Smad3 mediates immediate early induction of Id1 by TGF- β . *Cell Research*, 19, 140–148. <https://doi.org/10.1038/cr.2008.321>
22. Lu, J., Wu, Y., Sousa, N., and Almeida, O. F. (2005). SMAD pathway mediation of BDNF and TGF beta 2 regulation of proliferation and differentiation of hippocampal granule neurons. *Development*, 132(14), 3231–3242. <https://doi.org/10.1242/dev.01893>
23. Ullah, I., Sun, W., Tang, L., and Feng, J. (2018). Roles of Smads Family and Alternative Splicing Variants of Smad4 in Different Cancers. *Journal of Cancer*, 9(21), 4018–4028.
<https://doi.org/10.7150%2Fjca.20906>
24. Hester, M., Thompson, J. C., Mills, J., Liu, Y., El-Hodiri, H. M., and Weinstein, M. (2005). Smad1 and Smad8 function similarly in mammalian central nervous system development. *Molecular and cellular biology*, 25(11), 4683–4692. <https://doi.org/10.1128/MCB.25.11.4683-4692.2005>
25. Xie, Z., Chen, Y., Li, Z., Bai, G., Zhu, Y., Yan, R., Tan, F., Chen, Y., Guillemot, F., Li, L., and Jing, N. (2011). Smad6 promotes neuronal differentiation in the intermediate zone of the dorsal neural tube by inhibition of the Wnt/ β -catenin pathway. *PNAS*, 108(29), 12119–12124.
<https://doi.org/10.1073%2Fpnas.1100160108>
26. Weizmann Institute of Science. (2023). SMAD2 Gene - SMAD Family Member 2. GeneCards. <https://www.genecards.org/cgi-bin/carddisp.pl?gene=SMAD2&keywords=SMAD2>
27. Weizmann Institute of Science. (2023). SMAD3 Gene - SMAD Family Member 3. GeneCards. <https://www.genecards.org/cgi-bin/carddisp.pl?gene=SMAD3&keywords=SMAD2>

28. Krampert, M., Chirasani, S. R., Wachs, F., Aigner, R., Bogdahn, U., Yingling, J. M., Heldin, C., Aigner, L., and Heuchel, R. (2010). Smad7 Regulates the Adult Neural Stem/Progenitor Cell Pool in a Transforming Growth Factor β - and Bone Morphogenetic Protein-Independent Manner. *Molecular and Cellular Biology*, 30(14), 3685–3694. <https://doi.org/10.1128%2FMCB.00434-09>
29. Tedeschi, A., and Giovanni, S. D. (2009). The non-apoptotic role of p53 in neuronal biology: enlightening the dark side of the moon. *EMBO Reports*, 10(6), 576–583. <https://doi.org/10.1038%2Fembor.2009.89>
30. Chen, J. (2016). The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression. *Cold Spring Harbor Perspectives in Medicine*, 6(3). <https://doi.org/10.1101%2Fcshperspect.a026104>
31. Kumar, P., Naumann, U., Aigner, L., Wischhusen, J., Beier, C. P., and Beier, D. (2015). Impaired TGF- β induced growth inhibition contributes to the increased proliferation rate of neural stem cells harboring mutant p53. *American Journal of Cancer Research*, 5(11), 3436–3445. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4697689/>
32. P13405 · RB_MOUSE. (n.d.) UniProt. Retrieved August 2, 2023, from <https://www.uniprot.org/uniprotkb/P13405/entry#sequences>
33. P25233 · NECD_MOUSE. (n.d.) UniProt. Retrieved August 2, 2023, from <https://www.uniprot.org/uniprotkb/P25233/entry#structure>
34. Miller, F. D., Pozniak, C. D., and Walsh, G.S. (2000). Neuronal life and death: an essential role for the p53 family. *Cell Death and Differentiation*, 7, 880-888. <https://doi.org/10.1038/sj.cdd.4400736>
35. Gilley, J., Coffey, P. J., and Ham, J. (2003). FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. *The Journal of Cell Biology*, 162(4), 613-622. <http://www.jcb.org/cgi/doi/10.1083/jcb.200303026>
36. Frade, J. M., and Ovejero-Benito, M. C. (2015). Neuronal cell cycle: the neuron itself and its circumstances. *Cell Cycle*, 14(5), 712–720. <https://doi.org/10.1080%2F15384101.2015.1004937>
37. Estus, S., Zaks, W. J., Freeman, R. S., Gruda, M., Bravo, R., and Johnson, E. M. Jr. (1994). Altered Gene Expression in Neurons during Programmed Cell Death: Identification of c-jun as Necessary for Neuronal Apoptosis. *The Journal of Cell Biology*, 23(6), 1717-1727. <https://rupress.org/jcb/article-pdf/127/6/1717/1264468/1717.pdf>
38. Bashari, D., Hacohen, D., Ginsberg, D. (2011). JNK activation is regulated by E2F and promotes E2F1-induced apoptosis. *Cellular Signaling*, 23(1), 65-70. <https://www.sciencedirect.com/science/article/abs/pii/S0898656810002317>

39. Reddy, C. E., Albanito, L., De Marco, P., Aiello, D., Maggiolini, M., Napoli, A., and Musti, A. M. (2013). Multisite phosphorylation of c-Jun at threonine 91/93/95 triggers the onset of c-Jun pro-apoptotic activity in cerebellar granule neurons. *Cell Death and Disease*, 4. <https://doi.org/10.1038/cddis.2013.381>
40. Hershko, T., Chaussepied, M., Oren, M., and Ginsberg, D. (2005). Novel link between E2F and p53: proapoptotic cofactors of p53 are transcriptionally upregulated by E2F. *Cell death and differentiation*, 12(4), 377–383. <https://doi.org/10.1038/sj.cdd.4401575>
41. Wang, D. B., Kinoshita, C., Kinoshita, Y., and Morrison, R. S. (2015). p53 and Mitochondrial Function in Neurons. *Biochimica et Biophysica Acta*, 1842(8), 1186-1197. <https://doi.org/10.1016/j.bbadis.2013.12.015>
42. Nakamizo, A., Amano, T., Zhang, W., Zhang, X., Ramadas, L., Liu, T., Bekele, B. N., Shono, T., Sasaki, T., Benedict, W. F., Sawaya, R., and Lang, F. F. (2008) Phosphorylation of Thr18 and Ser20 of p53 in Ad-p53–induced apoptosis. *Neuro-Oncology*, 10(3), 275–291. <https://doi.org/10.1215/15228517-2008-015>
43. Yogosawa, S., and Yoshida, K. (2018). Tumor suppressive role for kinases phosphorylating p53 in DNA damage-induced apoptosis. *Cancer Science*, 109(11), 3376–3382. <https://doi.org/10.1111%2Fcas.13792>
44. Thompson, T., Tovar, C., Yang, H., Carvajal, D., Vu, B. T., Xu, Q., Wahl, G. M., Heimbrook, D. C., and Vassilev, L. T. (2004). Phosphorylation of p53 on Key Serines Is Dispensable for Transcriptional Activation and Apoptosis. *Protein Synthesis, Post-Translational Modification, and Degradation*, 279(51), 53015-53022. <https://doi.org/10.1074/jbc.M410233200>
45. Loughery, J., Cox, M., Smith, L. M., and Meek, D. W. (2014). Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters. *Nucleic Acids Research*, 42(12), 7666–7680. <https://doi.org/10.1093/nar/gku501>
46. Pleasure, D. E. (1999). Regeneration in the Central and Peripheral Nervous Systems. *Basic Neurochemistry: Molecular, Cellular and Medical Aspects*, 6. <https://www.ncbi.nlm.nih.gov/books/NBK28114/>
47. Cui, J., and Placzek, W. J. (2018). Post-Transcriptional Regulation of Anti-Apoptotic BCL2 Family Members. *International Journal of Molecular Sciences*, 19(1). <https://doi.org/10.3390/ijms19010308>
48. Huang, D. C., O'Reilly, L. A., Strasser, A., and Cory, S. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. *The EMBO Journal*, 16(5). <https://doi.org/10.1093/emboj/16.15.4628>

49. Merry, D.E., Veis, D.J., Hickey, W. F., Korsmeyer, S.J. (1994). Bcl-2 protein expression is widespread in the developing nervous system and retained in the adult PNS. *Development*, 120(2). <https://doi.org/10.1242/dev.120.2.301>
50. Kuhn, H. G., Eisch, A. J., Spalding, K., and Peterson, D. A. (2016). Detection and Phenotypic Characterization of Adult Neurogenesis. *Cold Spring Harbor Perspectives in Biology*, 8(3). <https://doi.org/10.1101/cshperspect.a025981>
51. Herrup, K., Neve, R., Ackerman, S.L., Ackerman, C. (2004). Divide and Die: Cell Cycle Events as Triggers of Nerve Cell Death. *Journal of Neuroscience*, 24(42). <https://doi.org/10.1523/JNEUROSCI.3347-04.2004>
52. Yang, Y., and Herrup, K. (2007). Cell division in the CNS: Protective response or lethal event in post-mitotic neurons. *Molecular Basis of Disease*, 1772(4). <https://doi.org/10.1016/j.bbadis.2006.10.002>
53. Nandakumar, S., Rozich, E., and Buttitta, L. (2021). Cell Cycle Re-entry in the Nervous System: From Polyploidy to Neurodegeneration. *Frontiers in Cell and Developmental Biology*, 9. <https://doi.org/10.3389/fcell.2021.698661>